cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
== Publications == Pratley, Richard E; Nauck, Michael; Bailey, Timothy; Montanya, Eduard; Cuddihy, Robert; Filetti, Sebastiano; Thomsen, Anne Bloch; Søndergaard, Rie Elvang; Davies, Melanie (2010). "Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial". The Lancet. 375 (9724): 1447–56. doi:10.1016/S0140-6736(10)60307-8. PMID 20417856. S2CID 3291387. Buse, John B; Rosenstock, Julio; Sesti, Giorgio; Schmidt, Wolfgang E; Montanya, Eduard; Brett, Jason H; Zychma, Marcin; Blonde, Lawrence (2009). "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)". The Lancet. 374 (9683): 39–47. doi:10.1016/S0140-6736(09)60659-0. PMID 19515413. S2CID 25135640. Jensterle, M.; Sebestjen, M.; Janez, A.; Prezelj, J.; Kocjan, T.; Keber, I.; Pfeifer, M. (2008). "Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome". European Journal of Endocrinology. 159 (4): 399–406. doi:10.1530/EJE-08-0507. PMID 18653546. Jensterle, M; Weber, M; Pfeifer, M; Prezelj, J; Pfutzner, A; Janez, A (2008). "Assessment of insulin resistance in young women with polycystic ovary syndrome". International Journal of Gynecology & Obstetrics. 102 (2): 137–40. doi:10.1016/j.ijgo.2008.03.017. PMID 18504045. S2CID 13513083. Jensterle, M.; Janez, A.; Mlinar, B.; Marc, J.; Prezelj, J.; Pfeifer, M. (2008).
== Formulation == Ampicillin-sulbactam only comes in a parenteral formulation to be either used as intravenous or intramuscular injections, and can be formulated for intravenous infusion. It is formulated in a 2:1 ratio of ampicillin:sulbactam. The commercial preparations available include:
However, the tropical Pacific experiences occasional shifts away from these average conditions. If the trade winds (blowing from east to west) are weaker than average, then both the upwelling in the East Pacific and the flow of warmer ocean surface waters towards the West Pacific lessen. This results in a cooler West Pacific and a warmer East Pacific, leading to a shift of cloud and rain towards the East Pacific. This situation is called El Niño. The opposite occurs if trade winds are stronger than average, leading to a warmer West Pacific and a cooler East Pacific. This situation is called La Niña and is associated with increased cloudiness and rainfall over the West Pacific.
Sources: en.wikipedia.org
== Career == Appointed by the Federal Decree No. (91) of 2006 issued by His Highness the Head of State for National Security Advisor. Vice President of the Executive Council of Abu Dhabi Emirate. Chairman of the Emirates Identity Authority. Al Ain Club Chairman of Board of Directors Vice-president of the executive board and of the honorary board Abu Dhabi Sports Council, chairman Abu Dhabi Combat Club, president In 2006, he was elected as Chairman of First Gulf Bank. He succeeded to the chairman position from Sheikh Mansour bin Zayed Al Nahyan, his other brother. On 12 December 2010, he was appointed a member of Executive Council of Abu Dhabi.
=== Artistic use === Synthetic colorants gained popularity as quickly with artists as with industry. The painters of the impressionist school in particular were famous early adopters. Critical reviews of Impressionists’ blues made comparisons to laundresses’ tubs, in particular the practice of laundry bluing, and to chemical waste dumped into the Seine by dye factories. One critic accused Edgar Degas, known for experiments in aquatint, pastel and oil painting as having an obsession with "chemistry," evoking a laboratory in description of his studio. Interestingly, Degas was known to be in correspondence with chemist Marcellin Berthelot, considered the father of organic synthetic chemistry in France. Pierre-Auguste Renoir’s later paintings relied heavily on alizarin crimson. He also employed cobalt blue or a mixture of ultramarine and cobalt blue, a synthetic pigment. New pigments and dyes were not limited to the artists of Europe, even Japanese printmakers were using dyes like rosaniline as early as 1863.
=== Properties === Like other peptides belonging to the super-family of the ICK, GsMTx-4 is amphipathic. Therefore, GsMTx-4 is able to interact with the hydrophobic side of the lipid bilayer. It can insert itself into the membrane by binding to anionic and cationic groups based on hydrophobic and electrostatic interactions. However, GsMTx-4 has a weak selectivity for the anionic phospholipids over the zwitterionic phospholipids of the lipid bilayer compared to other ICK peptides. For all ICK blocker peptides, the dominating aromatic residues in the hydrophobic face are widely considered to promote the binding and adsorption of the peptide to the lipid bilayer by positively contributing to its bilayer partitioning energy. Compared with other ICK peptides, GsMTx-4 has a relatively high content of lysine residues, which causes the peptide to be more positively charged. This is important for its orientation and depth of the peptide penetration into the lipid bilayer.
Sources: en.wikipedia.org
Valve has released two versions of a game controller aimed to be used for Steam games, the Steam Controller. The first model was released in November 2015, alongside the original Steam Machine concept, while the second was released in May 2026 ahead of Valve's dedciated Steam Machine model and Steam Frame. Among other features, both generations of the controller use two small trackpads with haptic feedback which can be used either as traditional controller actions like a joystick, but also like a computer mouse input to control many personal computer games that lack traditional controller support.
The calcitonin receptor (CT) is a G protein-coupled receptor that binds the peptide hormone calcitonin and is involved in maintenance of calcium homeostasis, particularly with respect to bone formation and metabolism. CT works by activating the G-proteins Gs and Gq often found on osteoclasts, on cells in the kidney, and on cells in a number of regions of the brain. It may also affect the ovaries in women and the testes in men. The function of the CT receptor protein is modified through its interaction with Receptor activity-modifying proteins (RAMPs), forming the multimeric amylin receptors AMY1 (CT + RAMP1), AMY2 (CT + RAMP2), and AMY3 (CT+ RAMP3). Preclinical studies have suggested that dual amylin and calcitonin receptor agonists may be more effective than amylin receptor agonists for obesity and type II diabetes.
Hahn spent February to June 1933 in the United States and Canada as a visiting professor at Cornell University. He gave an interview to the Toronto Star Weekly in which he painted a flattering portrait of Adolf Hitler: I am not a Nazi. But Hitler is the hope, the powerful hope, of German youth... At least 20 million people revere him. He began as a nobody, and you see what he has become in ten years.... In any case for the youth, for the nation of the future, Hitler is a hero, a Führer, a saint... In his daily life he is almost a saint. No alcohol, not even tobacco, no meat, no women. In a word: Hitler is an unequivocal Christ. The April 1933 Law for the Restoration of the Professional Civil Service banned Jews and communists from academia. Meitner was exempt from its impact because she was an Austrian rather than a German citizen. Haber was likewise exempt as a veteran of World War I, but chose to resign his directorship of the Kaiser Wilhelm Institute of Physical Chemistry and Electrochemistry in protest on 30 April 1933. The directors of the other Kaiser Wilhelm Institutes, even the Jewish ones, complied with the new law, which applied to the KWS as a whole and those Kaiser Wilhelm institutes with more than 50% state support, which exempted the KWI for Chemistry. Hahn therefore did not have to fire any of his own full-time staff, but as the interim director of Haber's institute, he dismissed a quarter of its staff, including three department heads. Gerhart Jander was appointed the new director of Haber's old institute, and reoriented it towards chemical warfare research.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.